ethyl (all-Z)-2-methyl-4,7,10,13,16,19-docosahexaenoate | 914294-14-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: ethyl (all-Z)-2-methyl-4,7,10,13,16,19-docosahexaenoate
• 英文别名: ethyl (4Z,7Z,10Z,13Z,16Z,19Z)-2-methyldocosa-4,7,10,13,16,19-hexaenoate
• CAS: 914294-14-7
• 化学式: C₂₅H₃₈O₂
• 分子量: 370.576
• InChiKey: KJCGGLMUDPRJCG-WSDBEMKQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.5
• 重原子数：
  27
• 可旋转键数：
  16
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  ethyl (all-Z)-2-methyl-4,7,10,13,16,19-docosahexaenoate 在 水 、 lithium hydroxide 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 18.0h， 以81%的产率得到α-methyl DHA
  参考文献：
  名称：

  [EN] LIPID COMPOUNDS AND COMPOSITIONS AND THEIR OPTHALMIC USE
  [FR] COMPOSÉS LIPIDIQUES ET COMPOSITIONS ASSOCIÉES ET LEUR UTILISATION OPHTALMIQUE

  摘要：

  本发明涉及用于预防或治疗如视网膜退行性疾病和眼部炎症疾病的眼科疾病的一类脂质化合物公式(I)及其药用可接受盐：(I)（其中R1为C9至C22的烷基或具有1至6个双键的C9至C22的烯基；R2选自卤素原子、羟基、烷基、烷氧基、烷硫基、羧基、酰基、氨基和烷基氨基的组；R3为氢原子或R2基团；R4为羧酸或其衍生物；X为亚甲基(-CH2-)，或氧或硫原子）。

  公开号：

  WO2017093732A1
• 作为产物：
  描述：

  (4Z,7Z,10Z,13Z,16Z,19Z)-4,7,10,13,16,19-二十二碳六烯酸乙酯 、 碘甲烷 在 正丁基锂 、 二异丙胺 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 1.0h， 以100%的产率得到ethyl (all-Z)-2-methyl-4,7,10,13,16,19-docosahexaenoate
  参考文献：
  名称：

  [EN] LIPID COMPOUNDS AND COMPOSITIONS AND THEIR OPTHALMIC USE
  [FR] COMPOSÉS LIPIDIQUES ET COMPOSITIONS ASSOCIÉES ET LEUR UTILISATION OPHTALMIQUE

  摘要：

  本发明涉及用于预防或治疗如视网膜退行性疾病和眼部炎症疾病的眼科疾病的一类脂质化合物公式(I)及其药用可接受盐：(I)（其中R1为C9至C22的烷基或具有1至6个双键的C9至C22的烯基；R2选自卤素原子、羟基、烷基、烷氧基、烷硫基、羧基、酰基、氨基和烷基氨基的组；R3为氢原子或R2基团；R4为羧酸或其衍生物；X为亚甲基(-CH2-)，或氧或硫原子）。

  公开号：

  WO2017093732A1

文献信息

• NEW DHA DERIVATIVES AND THEIR USE AS MEDICAMENTS
  申请人：Pronova BioPharma Norge AS

  公开号：EP1888727B1

  公开（公告）日：2015-04-15
• Novel compounds
  申请人：Bryhn Morten

  公开号：US20070088170A1

  公开（公告）日：2007-04-19

  Compounds of formula (I); wherein R 1 and R 2 are the same or different and may be selected from the group consisting of a hydrogen atom, a hydroxy group, an alkyl group, a halogen atom, an alkoxy group, an acyloxy group, an acyl group, an alkenyl group, an alkynyl group, an aryl group, an alkylthio group, an alkoxycarbonyl group, an alkylsulfinyl group, an alkylsulfonyl group, an amino group, and an alkylamino group; and X represents a carboxylic acid group, a carboxylate group, or a carboxamide group; or any pharmaceutically acceptable salt, solvate, complex or pro-drug thereof, with the provisos that the compound of formula (I) is not (all-Z)-4,7,10,13,16,19-docosahexaenoic acid (DHA), alpha-methyl DHA, alpha-methyl DHA methyl ester, alpha-methyl DHA ethyl ester or alpha-hydroxy DHA ethyl ester, are disclosed. A fatty acid composition and a pharmaceutical composition comprising such compounds are also disclosed. The use of such compounds as medicaments, in particular for the treatment of diabetes type 2, is also disclosed.
• Novel Compounds
  申请人：Bryhn Morten

  公开号：US20080300306A1

  公开（公告）日：2008-12-04

  Compounds of formula (I); wherein R 1 and R 2 are the same or different and may be selected from the group consisting of a hydrogen atom, a hydroxy group, an alkyl group, a halogen atom, an alkoxy group, an acyloxy group, an acyl group, an alkenyl group, an alkynyl group, an aryl group, an alkylthio group, an alkoxycarbonyl group, an alkylsulfinyl group, an alkylsulfonyl group, an amino group, and an alkylamino group; and X represents a carboxylic acid group, a carboxylate group, or a carboxamide group; or any pharmaceutically acceptable salt, solvate, complex or pro-drug thereof, with the provisos that the compound of formula (I) is not (all-Z)-4,7,10,13,16,19-docosahexaenoic acid (DHA), alpha-methyl-DHA, alpha-methyl DHA methyl ester, alpha-methyl-DHA ethyl ester or alpha-hydroxy DHA ethyl ester, are disclosed. A fatty acid composition and a pharmaceutical composition comprising such compounds are also disclosed. The use of such compounds as medicaments, in particular for the treatment of diabetes type 2, is also disclosed.
• FATTY ACID ANALOGUES, I.E. INCLUDING DHA DERIVATIVES FOR USES AS A MEDICAMENT
  申请人：Bryhn Morten

  公开号：US20090203778A1

  公开（公告）日：2009-08-13

  A compound of formula (I) wherein R 1 and R 2 are different and each is chosen from a methyl group and a hydrogen atom; wherein X is chosen from a carboxylic acid group, a carboxylate group, a carboxamide group; or any pharmaceutically acceptable salt, solvate, complex, or pro-drug of said compound. A pharmaceutical composition and a lipid composition comprising a compound of formula (I) is also disclosed. A method for the treatment of obesity, diabetes mellitus, amyloidos-related diseases, cardiovascular-diseases, and cerebrovascular diseases is also disclosed.
• COMPOSITION
  申请人：Holmeide Anne Kristin

  公开号：US20110166228A1

  公开（公告）日：2011-07-07

  The present invention relates to compositions comprising at least omega-3 lipid compounds substituted at the 2-positions having therapeutic activity. More specifically, the present invention relates to a composition comprising at least omega-3 lipid compounds substituted at the 2-position, counted from the functional group (X) of the omega-3 lipid compound, wherein the omega-3 lipid compounds comprise: a compound of general formula (I): and a compound of formula (II): wherein R 1 and R 2 are the same or different and are chosen from a hydrogen atom, a hydroxy group, an alkyl group, a halogen atom, an alkoxy group, an acyloxy group, an acyl group, an alkenyl group, an alkynyl group, an aryl group, an alkylthio group, an alkoxycarbonyl group, a carboxy group, an alkylsulfinyl group, an alkylsulfonyl group, an amino group, and an alkylamino group; and X represents a carboxylic acid or a derivative thereof, a carboxylate, a carboxylic anhydride, a hydroxymethyl (—CH 2 OH) or a pro-drug thereof, or a carboxamide, or any pharmaceutically acceptable complex, salt, solvate, or pro-drug, with the provisos that: R 1 and R 2 are not simultaneously hydrogen.